Forte Biosciences Sees Unusually Large Options Volume (NASDAQ:FBRX)

Forte Biosciences, Inc. (NASDAQ:FBRX) saw unusually large options trading on Wednesday. Stock investors acquired 30,205 call options on the company. This is an increase of 1,663% compared to the average volume of 1,713 call options.

Insider Transactions at Forte Biosciences

In other Forte Biosciences news, CFO Antony A. Riley acquired 22,514 shares of Forte Biosciences stock in a transaction dated Thursday, November 21st. The stock was purchased at an average cost of $5.55 per share, for a total transaction of $124,952.70. Following the completion of the acquisition, the chief financial officer now directly owns 30,776 shares of the company’s stock, valued at $170,806.80. This represents a 272.50 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 9.60% of the stock is owned by insiders.

Forte Biosciences Trading Down 6.4 %

Shares of NASDAQ:FBRX opened at $19.44 on Thursday. The stock has a market cap of $28.42 million, a PE ratio of -1.19 and a beta of 1.13. The stock’s fifty day simple moving average is $16.60 and its two-hundred day simple moving average is $7.69. Forte Biosciences has a 1-year low of $4.11 and a 1-year high of $28.68.

Analyst Upgrades and Downgrades

Separately, Chardan Capital reiterated a “buy” rating and set a $64.00 price target on shares of Forte Biosciences in a research note on Wednesday, December 4th.

About Forte Biosciences

Forte Biosciences, Inc operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc is headquartered in Dallas, Texas.